Dermira (DERM) Receives a Buy from Cantor Fitzgerald


In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Dermira (DERM), with a price target of $25. The company’s shares opened today at $10.50.

Chen noted:

“. Post a solid quarter of execution, we reiterate our OW rating and 12-month PT of $25 for DERM shares. The peak sales potential of Qbrexza for hyperhidrosis and lebrikizumab for AD are underappreciated, in our view. We also think DERM is an interesting company in a consolidating space. Therefore, we expect upward earnings revisions and multiple expansion to drive the stock higher.”

According to TipRanks.com, Chen is a 4-star analyst with an average return of 10.1% and a 42.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dermira with a $22.14 average price target, which is an 110.9% upside from current levels. In a report issued on April 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $22 price target.

See today’s analyst top recommended stocks >>

Based on Dermira’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $71.81 million. In comparison, last year the company had a GAAP net loss of $59.25 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts